IQVIA management check
IQV · Health Care · Life Sciences Tools & Services · CEO Ari Bousbib
Filings as of
Closest peers in Life Sciences Tools & Services
- 101WATWaters Corporation76
- 108MTDMettler Toledo76
- 151DHRDanaher Corporation72
- 168IQVIQVIA71
- 307TMOThermo Fisher Scientific61
- 375CRLCharles River Laboratories56
- 386AAgilent Technologies55
- 443ILMNIllumina, Inc.47
- 453TECHBio-Techne45
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
922ndDetail
$100 invested at the start of fiscal 2021 grew to $126, against $187 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9997thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.99 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch2.1% of net income
What does the CEO cost owners?
$28.1m pay · $1.4bn net income, FY2025
2428thDetail
$28.1m of reported pay in fiscal 2025, against $1.4bn of net income.
- WatchInsiders are selling
Do they own the stock?
6 mo: ▲ $0 bought · ▼ $31.1m sold
——Detail
6 insiders sold $31.1m in the last six months and none bought.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −3.5% a year; flagged above +2%
Stock pay 1.5% of revenue
9483rdDetail
Diluted shares changed -3.5% a year over the last three fiscal years. Stock-based pay was 1.5% of revenue in the latest year.
- Good4 leadership filings in 3 years
Is leadership stable?
4 filings under 8-K 5.02 in 3 years
CEO: Ari Bousbib
100100thDetail
CEO in the pay table: Ari Bousbib. 4 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed February 27, 2026.
Pay tied most to Adjusted Diluted EPS Growth
Other key measuresAdjusted Diluted EPS Growth (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57)Relative Total Stockholder Return (as defined in “Compensation Discussion and Analysis—Elements of Compensation— Long-Term Incentive Awards,” described on page 60)Revenue (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57)Adjusted EBITDA (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57)
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Ari Bousbib | $28.1m | $36.1m | $8.9m | $126 | $187 | $1.4bn |
| 2024 | — | $26.7m | $11.5m | $6.6m | $110 | $159 | $1.4bn |
| 2023 | — | $29.2m | $42.3m | $4.5m | $129 | $148 | $1.4bn |
| 2022 | — | $30.1m | $6.0m | $5.0m | $114 | $138 | $1.1bn |
| 2021 | — | $28.6m | $88.4m | $4.4m | $157 | $136 | $966.0m |
Insiders and the CEO's stakeSelling
6 insiders sold $31.1m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldAri BousbibSee Remarks$26.1mJul 29, 2026
- SoldEric SherbetSee Remarks$2.5mNov 9, 2026
- SoldW Richard StaubSee Remarks$1.3mAug 3, 2026
- SoldJames G. BerkshireSee Remarks$697kSep 2, 2026
Leadership and governance on file
All 9 filings
- Apr 23, 2026Leadership change8-K 5.02
- Nov 5, 2025Leadership change8-K 5.02
- Sep 2, 2025Leadership change8-K 5.02
- May 10, 2024Leadership change8-K 5.02
- Sep 26, 2023Leadership change8-K 5.02
- Oct 3, 2022Leadership change8-K 5.02
- Jul 29, 2022Leadership change8-K 5.02
- Mar 14, 2022Leadership change8-K 5.02
- Jan 27, 2022Leadership change8-K 5.02
Latest shareholder vote results: Apr 23, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $5.2bn returned to owners in buybacks and dividends, 84% of net income, and $1.0bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $13.9bn | $14.4bn | $15.0bn | $15.4bn | $16.3bn |
| Net income | $966.0m | $1.1bn | $1.4bn | $1.4bn | $1.4bn |
| Stock-based pay | $170.0m | $194.0m | $217.0m | $206.0m | $247.0m |
| Buybacks | $406.0m | $1.2bn | $992.0m | $1.4bn | $1.2bn |
| Dividends | — | — | — | — | — |
| Diluted shares | 195m | 191m | 186m | 183m | 174m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.